Black checkmark with a sparkle and a curved line underneath on a white background.
Company

MANGOCEUTICALS, INC.

Ticker
MGRX
Sector
Industry
Report date
November 17, 2026
Valye AI Score

100

Very high visibility
Recent developments
Recent developments summary

Recent developments highlight Mangoceuticals' strategic initiatives including investment raises, mergers, product launches, and patent acquisitions.

Recent developments:
  • Mangoceuticals announced proposed Series D Preferred Stock terms and combined 2025 and 2026 annual meeting date [N1].
  • The company secured a $2.5 million investment to advance antiviral intellectual property commercialization [N2].
  • Mangoceuticals announced a merger with Nuclea Energy to advance nuclear microreactor technology [N3].
  • The company expanded its patent portfolio in nutraceuticals [N4].
  • Reported 100% survival rates in field studies of MGX-0024 for poultry respiratory diseases [N5].
  • Entered the wellness pouch market and appointed Tim Corkum to lead the new unit [N6].
  • Acquired intellectual property assets from Smokeless Technology Corp. to expand into the oral pouch delivery market [N7].
  • Secured exclusive rights for plant-based nutriceutical Diabetinol® targeting pre-diabetes and weight management in the U.S. and Canada [N8].
Overview

Mangoceuticals, Inc. operates in pharmaceutical and nutraceutical sectors with a diversified portfolio including antiviral IP, wellness pouches, oral pouch delivery, and telehealth services. The company has engaged in mergers and acquisitions to expand its technology base, including a merger with Nuclea Energy to advance nuclear microreactor technology. It maintains material agreements with related-party pharmacy service providers and has secured exclusive rights for certain nutriceutical products. Financially, the company reported modest revenue and significant net losses in recent quarters, with liquidity ratios suggesting moderate ability to cover short-term obligations. Regulatory risks stem from reliance on compounding pharmacy exemptions and telehealth prescribing models, alongside risks related to Nasdaq listing compliance.

Executive summary

Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. Mangoceuticals, Inc. is engaged in pharmaceutical and nutraceutical product development and commercialization, including antiviral research, wellness products, and nuclear microreactor technology through a merger. The company has reported recent revenue and net losses, with liquidity ratios indicating moderate short-term financial stability. It faces regulatory and listing compliance risks, including Nasdaq continued listing requirements and FDA scrutiny of compounding pharmacy practices.

Scenarios for MGRX

Bull case model:

The company has demonstrated progress in antiviral research and poultry disease treatment with positive field study results. Expansion into wellness and oral pouch markets, along with telehealth brand launches, indicate diversification and innovation. Strategic mergers and patent acquisitions support technology advancement and market positioning. Exclusive rights to nutriceutical products targeting large markets such as pre-diabetes and weight management provide potential for growth in specialized health segments.

Bear case model:

Mangoceuticals faces significant regulatory risks due to its reliance on compounding pharmacy exemptions and telehealth prescribing models, which are under increased FDA scrutiny. The company is not currently compliant with Nasdaq listing requirements, risking delisting and reduced market liquidity. Financially, it reports net losses and limited revenue, with liquidity ratios indicating moderate short-term coverage but potential constraints. Exposure to digital asset holdings (USDT) introduces additional financial risk. Operational dependence on related-party agreements may also pose conflicts or vulnerabilities.

Moat:

Mangoceuticals' moat includes proprietary antiviral intellectual property, exclusive rights to plant-based nutriceuticals, and strategic acquisitions expanding its product portfolio and delivery methods. Its merger with Nuclea Energy introduces advanced nuclear microreactor technology, potentially differentiating its technology offerings. The company's relationships with related-party pharmacies and exclusive distribution agreements provide operational integration and market access advantages. However, regulatory scrutiny and compliance risks may challenge the sustainability of these advantages.

Risks overview
Risks summary
The most significant risks for Mangoceuticals include potential Nasdaq delisting due to non-compliance with listing standards and regulatory challenges related to its pharmacy compounding and telehealth business model.
Risks details:

• Nasdaq Listing Compliance Risk: The company is not currently in compliance with Nasdaq's minimum bid price and stockholders' equity requirements, facing potential delisting which could reduce liquidity and investor access.
• Regulatory Risk Related to Pharmacy Compounding and Telehealth: Reliance on a related-party pharmacy operating under Section 503A exposes the company to FDA scrutiny and potential enforcement actions if practices are deemed manufacturing rather than compounding.
• Financial Risk: Reported net losses and modest revenue, combined with liquidity ratios, indicate financial challenges that may affect operational flexibility and capital raising.
• Digital Asset Exposure Risk: Holdings in USDT stablecoin carry risks of loss, liquidity constraints, and regulatory developments that could adversely affect financial condition.

FINAL FORECAST FOR MGRX

Final take one line
Mangoceuticals exhibits diversified pharmaceutical and nutraceutical activities with significant regulatory and listing compliance risks.
Final take 12 to 24 month view

Business trends: Expansion through mergers, patent acquisitions, and diversified product launches in antiviral, wellness, and nuclear technology sectors.
Execution milestones: Completion of merger with Nuclea Energy, advancement of antiviral IP commercialization, and launch of new product categories including telehealth services.
Key risks: Regulatory scrutiny of compounding pharmacy and telehealth models, Nasdaq listing compliance challenges, financial losses, and exposure to digital asset volatility.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

100
LLM visibility overview
LLM Visibility known facts
  • Mangoceuticals, Inc. operates in pharmaceutical and nutraceutical sectors with activities including antiviral IP commercialization, nuclear microreactor advancement via merger, and expansion into wellness pouch and oral pouch delivery markets.
  • The company has reported 100% survival rates in field studies of MGX-0024 for poultry respiratory diseases, indicating active pharmaceutical research and development.
  • Mangoceuticals has secured exclusive rights for plant-based nutriceutical Diabetinol® targeting pre-diabetes and weight management in the U.S. and Canada.
  • The company launched PeachesRx, a women's telehealth brand for wellness and GLP-1 treatments.
  • Mangoceuticals has entered exclusive distribution agreements for its Dermytol® skincare line and acquired intellectual property assets from Smokeless Technology Corp.
  • Recent corporate actions include a proposed Series D Preferred Stock offering and a merger with Nuclea Energy to advance nuclear microreactor technology.
  • Financial snapshot as of 2026-09-30 shows cash and equivalents of $659,258, current assets of $1,491,551, current liabilities of $1,163,162, resulting in a current ratio of 1.28 and cash ratio of 0.57.
  • Revenue reported for the quarter ended 2026-06-30 was $68,757, with a net loss of $3,553,512 for the quarter ended 2026-09-30 and basic and diluted EPS of -$0.19.
  • The company has material agreements with related-party pharmacy Epiq Scripts for pharmacy consulting and services, including fees based on prescription pill sales and rights of first negotiation and refusal.
  • Mangoceuticals is not currently in compliance with Nasdaq listing requirements, including minimum bid price and stockholders' equity thresholds, and faces potential delisting risks.
  • The company relies on a related-party pharmacy operating under Section 503A of the FFD&C Act, exposing it to regulatory risks related to compounding pharmacy practices and telehealth prescribing models.
  • Mangoceuticals holds approximately $500,000 in Tether USD (USDT), a digital asset with associated liquidity and regulatory risks.
Sources
Sources - Context summary

Generated 2026-11-17

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-04-01 | 10-K
  • S2 | 2026-11-16 | 10-Q
Sources - News headlines
  • N1 | 2026-11-07 | www.nasdaq.com | Mangoceuticals, Inc. Announces Proposed Series D Preferred Stock Terms and Combined 2025 and 2026 Annual Meeting Date | https://www.nasdaq.com/articles/mangoceuticals-inc-announces-proposed-series-d-preferred-stock-terms-and-combined-2025-and
  • N2 | 2026-10-02 | www.nasdaq.com | Mangoceuticals Secures $2.5 Mln Investment To Advance Antiviral IP Commercialization | https://www.nasdaq.com/articles/mangoceuticals-secures-25-mln-investment-advance-antiviral-ip-commercialization
  • N3 | 2026-07-31 | www.nasdaq.com | Mangoceuticals To Merge With Nuclea Energy, Advancing Nuclear Microreactor; Stock Up | https://www.nasdaq.com/articles/mangoceuticals-merge-nuclea-energy-advancing-nuclear-microreactor-stock
  • N4 | 2026-04-02 | www.nasdaq.com | Mangoceuticals Expands with Patent Acquisition in Nutraceuticals | https://www.nasdaq.com/articles/mangoceuticals-expands-patent-acquisition-nutraceuticals
  • N5 | 2025-05-27 | www.nasdaq.com | Mangoceuticals, Inc. Reports 100% Survival Rates in Field Studies of MGX-0024 for Poultry Respiratory Diseases | https://www.nasdaq.com/articles/mangoceuticals-inc-reports-100-survival-rates-field-studies-mgx-0024-poultry-respiratory
  • N6 | 2025-04-25 | www.nasdaq.com | Mangoceuticals Enters Wellness Pouch Market, Appoints Tim Corkum To Lead New Unit | https://www.nasdaq.com/articles/mangoceuticals-enters-wellness-pouch-market-appoints-tim-corkum-lead-new-unit
  • N7 | 2025-04-25 | www.nasdaq.com | Mangoceuticals Inc. Acquires Intellectual Property Assets from Smokeless Technology Corp. to Expand into Oral Pouch Delivery Market | https://www.nasdaq.com/articles/mangoceuticals-inc-acquires-intellectual-property-assets-smokeless-technology-corp-expand
  • N8 | 2025-03-25 | www.nasdaq.com | Mangoceuticals Secures Exclusive Rights for Plant-Based Nutriceutical Diabetinol® to Address Pre-Diabetes and Weight Management Market in U.S. and Canada | https://www.nasdaq.com/articles/mangoceuticals-secures-exclusive-rights-plant-based-nutriceutical-diabetinolr-address-pre
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine